KRRO
NASDAQ
$11.50
Korro Bio Inc (KRRO)
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $20 (+73.91%)
Market Cap
$188M
Free Cash Flow Yield
-37.57%
Beta (5Y)
2.13
Price Chart
Valuation
Market Cap$188M
P/S48.91
P/B1.60
Profitability
Total Revenue (TTM)$3.84M
Gross Profit (TTM)-$44M
EBITDA-$114M
Operating Margin-2154%
EPS-$11.34
Financial Health
Free Cash Flow Yield-37.57%
Growth & Risk
Revenue 5Y CAGR-35.48%
FCF 5Y CAGR+0.70%
Beta (5Y)2.13
Sharpe Ratio0.81